Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lidds ABFRA:5LD Equity-to-Asset is 0.76 as of Sep. 2025, which is 13% below its 10-year median of 0.87. The stock has 2 warning signs investors should review.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lidds AB's Total Stockholders Equity for the quarter that ended in Sep. 2025 was €0.14 Mil. Lidds AB's Total Assets for the quarter that ended in Sep. 2025 was €0.18 Mil.
The historical rank and industry rank for Lidds AB's Equity-to-Asset or its related term are showing as below:
FRA:5LD'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59 Med: 0.87 Max: 0.99
Current: 0.75
During the past 13 years, the highest Equity to Asset Ratio of Lidds AB was 0.99. The lowest was 0.59. And the median was 0.87.
FRA:5LD's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.68
vs FRA:5LD: 0.75
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Lidds AB Equity-to-Asset Related Terms
Lidds AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Lidds AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5LD vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Lidds AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lidds AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lidds AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Lidds AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Lidds AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lidds AB (FRA:5LD) has a Equity-to-Asset of 0.76 as of Sep. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lidds AB and its competitors. This is 13% below median its historical median of 0.87. Over the past decade, Lidds AB's Equity-to-Asset has ranged from 0.59 to 0.99.
Is Lidds AB's Equity-to-Asset too high?
Lidds AB's current Equity-to-Asset of 0.76 is 13% below median its 10-year median of 0.87. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 0.99. The Biotechnology industry median Equity-to-Asset is 0.68. Lidds AB's value of 0.76 is 11.8% above this industry median.
How does Lidds AB's Equity-to-Asset compare to VRTX and REGN?
Lidds AB's Equity-to-Asset of 0.76 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.68. Lidds AB's value of 0.76 is 11.8% above this benchmark. Historically, Lidds AB's own Equity-to-Asset has ranged from 0.59 to 0.99 over the past decade. While the company's 10-year median is 0.87 vs. the industry median of 0.68, Lidds AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lidds AB's current Equity-to-Asset of 0.76 is 11.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lidds AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lidds AB's current Equity-to-Asset is 0.76, which is 13% below median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lidds AB stock overvalued right now?
Lidds AB (FRA:5LD) has a current Equity-to-Asset of 0.76. The current Equity-to-Asset is 0.76, which is 13% below median its 10-year median of 0.87 and 11.8% above the Biotechnology industry median of 0.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Lidds AB (FRA:5LD), the current Equity-to-Asset is 0.76 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lidds AB is a Sweden-based drug delivery company focused on its proprietary NanoZolid technology platform. The NanoZolid system is used to formulate drugs for local administration with controlled and sustained release over extended periods. The company offers this technology to partners and is also developing its own pipeline of drug candidates, prominently in oncology, where the platform is used to enable localized and sustained drug delivery. It has a pipeline with several projects in clinical development, both in early- and late-stage clinical phases, and projects about to enter clinical development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5LD has been successfully added to your 
